Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline
Press Release Paris, 3rd March, 2025 Full-year 2024 results1: Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only partly offset by encouraging commercial momentumCore EBITDA at €50.4m, with margin down 370bps year-on-year to 5.5%, due notably to unfavorable fixed cost impact€(43.6) million EBITDA, including €87.1 mill